申请人:ADAMED SP. Z O.O
公开号:US20150051257A1
公开(公告)日:2015-02-19
Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted; or 9- or 10-membered bicyclic group, linked to —(O)
x
—(CH2)
y
— through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5- or 6-membered non-aromatic heterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C
1
-C
3
-alkyls; D represents a group selected from: phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted; thiophene unsubstituted or substituted; bicyclic group consisting of imidazolering fused with 5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2 heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring; and bicyclic group consisting of benzene ring fused with—or 6-membered non-aromatic heterocyclic ring having 1 or 2 heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon N atoms of benzene ring; R represents H or —CH 3; x is 0 or 1; y is 2 or 3; and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents —CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.
苯甲胺的磺胺基衍生物,其化学式(I)中,A代表未取代或取代的苯基;或与—(O)x—(CH2)y—连接的9-或10-成员双环族,通过其芳香碳原子之一,由与含1或2个异原子(N和O)中独立选择的群组成的芳香环并联的苯环构成,其中此类双环族未取代或取代,或者与含1或2个O原子的5-或6-成员非芳香杂环取代或未取代,其中杂环未取代或取代为一个或多个C1-C3-烷基;D代表选自:未取代或取代的苯基;未取代或取代的萘基;未取代或取代的噻吩基;由咪唑环并联的5-成员非芳香碳环组成的双环族;由苯环并联的含1或2个异原子(N、O和S)中独立选择的群组成的5-成员杂芳环,未取代或取代,并通过苯环的一个碳原子之一与磺胺基团连接;以及由苯环并联的含1或2个异原子(N和O)中独立选择的群组成的5-或6-成员非芳香杂环取代或未取代,并通过苯环的一个碳N原子之一与磺胺基团连接;R代表H或—CH3;x为0或1;y为2或3;以及其药学上可接受的盐和溶剂合物,但如果x为0且y为2,则D为未取代或取代的萘基,且如果R代表—CH3,则A不是未取代或取代的苯基。这些化合物可用于治疗和/或预防中枢神经系统疾病。